Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch
  

Roche Glycart Ag patents

Recent patent applications related to Roche Glycart Ag. Roche Glycart Ag is listed as an Agent/Assignee. Note: Roche Glycart Ag may have other listings under different names/spellings. We're not affiliated with Roche Glycart Ag, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Roche Glycart Ag-related inventors




Date Roche Glycart Ag patents (updated weekly) - BOOKMARK this page
09/14/17Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
07/13/17Bispecific antigen binding molecules
06/22/17Method and constructs for the ph dependent passage of the blood-brain-barrier
06/22/17Anti-her3 antibodies and uses thereof
05/18/17Antibody fc variants
04/20/17A-fucosylation detection in antibodies
03/30/17Novel immunoconjugates
03/02/17Combination il-2 immunoconjugate therapy
11/24/16Interleukin-10 fusion proteins and uses thereof
10/20/16Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
09/22/16Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
09/15/16Novel immunoconjugates
09/15/16Anti-tenascin-c a2 antibodies and methods of use
08/11/16Anti-cea antibodies
07/21/16Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
07/21/16Mutant interleukin-2 polypeptides
06/16/16Combination therapy of an afucosylated cd20 antibody with bendamustine
05/26/16Bispecific t cell activating antigen binding molecules
05/12/16Fc-free antibodies comprising two fab-fragments and methods of use
03/31/16Interleukin-2 fusion proteins and uses thereof
03/24/16Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class 1 compromising multi-function proteins
03/17/16Antigen binding molecules with increased fc receptor binding affinity and effector function
03/17/16Antigen binding molecules with increased fc receptor binding affinity and effector function
03/17/16Antibodies to carcinoembryonic antigen (cea), methods of making same, and uses thereof
03/17/16Antigen binding molecules with increased fc receptor binding affinity and effector function
03/03/16In vivo adcc model
03/03/16Anti-fap antibodies and methods of use
03/03/16Anti-fap antibodies and methods of use
01/21/16Combination therapy of an afucosylated cd20 antibody with an anti-vegf
01/07/16Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)
01/07/16Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor
12/03/15Modified antigen binding molecules with altered cell signaling activity
12/03/15Modified antigen binding molecules with altered cell signaling activity
10/22/15Asgpr antibodies and uses thereof
10/01/15Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
10/01/15Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
10/01/15Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
09/24/15Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
08/27/15Antibody fc variants
04/02/15Combination therapy of an afucosylated cd20 antibody with bendamustine
03/19/15Combination therapy
03/19/15Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
03/12/15Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
12/25/14Anti-her3 antibodies and uses thereof
12/25/14Anti-her3 antibodies and uses thereof
12/18/14Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
10/30/14Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody
10/09/14A-fucosylation detection in antibodies
10/02/14Combination therapy with type i and type ii anti-cd20 antibodies
09/11/14Separation fucosylated antibodies
08/28/14Bispecific t cell activating antigen binding molecules
08/28/14Bispecific t cell activating antigen binding molecules
08/28/14Anti-mcsp antibodies
08/14/14Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
08/14/14Predictive biomarker for cancer treatment with adcc-enhanced antibodies
07/31/14Anti-cea antibodies
07/10/14Bispecific anti-egfr/anti igf-1r antibodies
05/22/14Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
05/15/14Bispecific anti erbb3 / anti cmet antibodies
03/13/14Immunotherapy
03/13/14Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
03/06/14Immunotherapy
03/06/14Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)
02/13/14Interleukin-10 fusion proteins and uses thereof
02/13/14Interleukin-2 fusion proteins and uses thereof
Patent Packs
02/13/14Combination therapy of an afucosylated cd20 antibody with bendamustine
01/09/14Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
10/17/13Bispecific anti erbb2/anti cmet antibodies
08/15/13Humanized anti-cdcp1 antibodies
08/01/13Predictive biomarker for cancer treatment with adcc-enhanced antibodies
06/20/13Bispecific anti erbb1 / anti cmet antibodies
11/08/12Method and constructs for the ph dependent passage of the blood-brain-barrier
10/04/12Anti-cea antibodies
07/19/12Bispecific death receptor agonistic antibodies
05/17/12Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
02/16/12Anti-tenascin-c a2 antibodies and methods of use
12/01/11Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
12/01/11Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
06/16/11Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
05/05/11Antibodies to carcinoembryonic antigen (cea), methods of making same, and uses thereof
Patent Packs
03/17/11Targeted immunoconjugates
03/03/11Humanized anti-cdcp1 antibodies







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Roche Glycart Ag in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roche Glycart Ag with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';